| OMB APPROVAL |
| OMB Number: 3235-0145 |
| Expires: December 31, 2005 |
| Estimated average burden hours per response...11 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Introgen Therapeutics, Inc.
Common Stock, $0.001 par value
46119F 10 7
December 31, 2002
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1 (b)
o Rule 13d-1 (c)
x Rule 13d-1 (d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).
| 13G | ||||||
| CUSIP No. 46119F 10 7 | ||||||
| 1. | Name of Reporting Person: David G. Nance |
I.R.S. Identification Nos. of above persons (entities only): |
||||
| 2. | Check the Appropriate Box if a Member of a Group: | |||||
| (a) | o | |||||
| (b) | o | |||||
| 3. | SEC Use Only: | |||||
| 4. | Citizenship or Place of Organization: United States Citizen |
|||||
| Number of Shares Beneficially Owned by Each Reporting Person With | ||||||
| 5. | Sole Voting Power: 2,707,885 | |||||
| 6. | Shared Voting Power: 0 | |||||
| 7. |
Sole Dispositive Power: 2,707,885 | |||||
| 8. | Shared Dispositive Power: 0 | |||||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person: 2,707,885 |
|||||
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares: o |
|||||
| 11. | Percent of Class Represented by Amount in Row (9): 12.3% | |||||
| 12. | Type of Reporting Person: IN | |||||
2
13G
| Item 1. | |||
| (a) | Name of Issuer: | ||
| Introgen Therapeutics, Inc., a Delaware corporation | |||
| (b) | Address of Issuer's Principal Executive Offices: | ||
| 301 Congress Ave., Suite 1850 Austin, Texas 78701 |
|||
| Item 2. | |||
| (a) | Name of Person Filing: | ||
| David G. Nance | |||
| (b) | Address of Principal Business Office or, if none, Residence: | ||
| 301 Congress Ave., Suite 1850 Austin, Texas 78701 |
|||
| (c) | Citizenship: | ||
| USA | |||
| (d) | Title of Class of Securities: | ||
| Common Stock, par value $ 0.001 per share | |||
| (e) | CUSIP Number: | ||
| 46119F 10 7 | |||
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | ||
| x | Not Applicable. | ||
| (a) | o | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). | |
| (b) | o | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). | |
| (c) | o | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). | |
| (d) | o | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | o | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |
| (f) | o | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
| (g) | o | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); | |
| (h) | o | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
| (i) | o | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | o | Group, in accordance with §240.13d-1(b)(1)(ii)(J). | |
3
13G
| Item 4. | Ownership. | ||
| (a) | Amount beneficially owned: | ||
| 2,707,885 | |||
| (b) | Percent of class: | ||
| 12.3% | |||
| (c) | Number of shares as to which the person has: | ||
| (i) | Sole power to vote or to direct the vote: | ||
| 2,707,885 | |||
| (ii) | Shared power to vote or to direct the vote: | ||
| 0 | |||
| (iii) | Sole power to dispose or to direct the disposition of: | ||
| 2,707,885 | |||
| (iv) | Shared power to dispose or to direct the disposition of: | ||
| 0 | |||
| Item 5. | Ownership of Five Percent or Less of a Class. | ||
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o. | |||
| NOT APPLICABLE | |||
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. | ||
| Reporting Person has the right to receive and the power to direct the receipt of dividends from or the proceeds from the sale of 2,215,605 shares by virtue of his position as the Chief Executive Officer and sole stockholder of Domecq Technologies and as the Chief Executive officer of each of Developtech Resources Corporation and Debouchement, Ltd. | |||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. | ||
| NOT APPLICABLE | |||
| Item 8. | Identification and Classification of Members of the Group. | ||
| NOT APPLICABLE | |||
| Item 9. | Notice of Dissolution of Group. | ||
| NOT APPLICABLE | |||
4
13G
| Item 10. | Certification. | ||
| (a) | Not applicable. | ||
| (b) | Not applicable. | ||
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Date: | February 13, 2003 |
| Signature: | /s/ DAVID NANCE |
| Name/Title: | DAVID NANCE |
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
5